国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
米氮平与曲唑酮、马普替林治疗抑郁症对照研究
Study of the Treatment of Depression with Mirtazapine, Trazodone and Maprotine
投稿时间:2005-12-20  
DOI:
中文关键词:  米氮平  曲唑酮  马普替林  抑郁症
英文关键词:Mirtazapine  Trazodone  Maprotine  Depression
基金项目:
姚晓伟
浙江省丽水学院医学部,浙江丽水323000
摘要点击次数: 1904
全文下载次数: 109
中文摘要:
      目的:评价米氮平与曲唑酮、马普替林治疗抑郁症的疗效及不良反应。方法:将符合《中国精神障碍分类与诊断标准》第3版诊断标准的抑郁症住院和门诊患者121例,随机平分为三组,分别给予米氮平和曲唑酮、马普替林治疗,疗程6周。用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度(CGI-S1)和不良反应量表(TESS),评定疗效和不良反应。结果:6周治疗后,3组总分均有显著下降,3组间疗效比较差异无统计学意义(P〉0、05)。结论:米氮平能更迅速的起效,对抑郁症的各个症状均有突出表现,是一种安全、有效的抗抑郁药。
英文摘要:
      Objective: To compare the efficacy and side effects of remeron, trazodone and maprotine in the treatment of depression. Method: In this study, 121 patients with diagnostic depression according to CCMD-3 were randomly assigned to remeron group, trazodone group and maprotine group and the treatment lasted 6 weeks. Their effects and side reactions were evaluated by means of HAMD, HAMA, CCI-SI and TESS before and after the treatment. Result: Remeron produced quicker effects and its side effects were fewer than those of trazodone and maprotine. Conclusion: Remeron's rapid effect is prominent on all symptoms of depression. Remeron is an effective and safe antidepressant.
查看全文  查看/发表评论  下载PDF阅读器
关闭